Chargement de l’entreprise
Just reported
Q3 2026 results
From Edwards Lifesciences's results release of 4 novembre 2026; its quarterly report has since been filed.
Revenue
Actual
1,72B $US
+10 % y/y
-1,5 % q/qGuided
1,67B $US
midpoint
Above guide+2,7 %EPS, GAAP
Actual
0,53 $US
+6,0 % y/y
+26 % q/qGuided
—
No guide given
Operating income, GAAP
Actual
299,1M $US
-2,6 % y/y
-42 % q/qGuided
—
No guide given
Company outlook
Q4 2026
- Revenue1,67B $US – 1,75B $US+8,9 % y/y First given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Edwards Lifesciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Medical Devices
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plc129,2B $USA+
SYKStryker Corp.118,9B $USA+
GEHCGE Healthcare Technologies Inc.37B $USA
GKOSGlaukos Corp14,6B $USA
PENPenumbra, Inc12,6B $USA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
BIIBBiogen Inc.28 oct. 2026BAGraded B, now A- GEHCGE Healthcare Technologies Inc.28 oct. 2026CAGraded C, now A
Comment elle gagne de l'argent
- Catheter-delivered aortic valve replacement72 %
- Catheter-delivered mitral and tricuspid valve repair and replacement11 %
- Surgical heart valve products16 %
Les parts du chiffre d'affaires sont des estimations pour nine months ended September 30, 2026, pas des chiffres tirés d'un document officiel.
En concurrence avec
Ce qu'elle vend5
SAPIEN
A family of tissue valves delivered through a catheter to replace a diseased aortic valve; some systems are also used for pulmonary valve replacement.
PASCAL
A catheter-delivered device that helps bring together the leaflets of a leaking mitral or tricuspid valve.
EVOQUE
A tissue valve delivered through a catheter to replace a leaking tricuspid valve.
Afficher 2 de plus
SAPIEN M3
A tissue valve delivered through a catheter to replace a diseased mitral valve.
INSPIRIS RESILIA, KONECT RESILIA, and MITRIS RESILIA
Surgical tissue valve products for aortic and mitral valve replacement; KONECT is a tissue valve conduit used in complex combined procedures.
Qui l'achète3
- Hospitals and health systems buy devices directly from Edwards sales teams or through distributors; in the United States, sales are mainly direct.
- Hospital purchasing groups and healthcare networks negotiate supplier contracts on behalf of hospitals.
- Heart specialists, including cardiac surgeons and interventional cardiologists, use the devices and take part in choosing treatments.
Sur quoi elle repose, et ce qui pourrait la briser
Ce dont l'activité dépend
- 1A large part of the business depends on hospitals adopting catheter-delivered aortic valve replacement and on clinicians choosing Edwards devices.
- 2Sales depend in part on government and private insurers covering procedures and paying hospitals enough to support their use.
- 3Some materials and components come from single-source suppliers; switching critical suppliers can require lengthy regulatory review.
- 4The company relies on clinical studies and regulatory clearances or approvals to bring devices to market and expand their permitted uses.
Ce qui pourrait mal tourner
- 1If clinical studies do not show the needed results, or regulators do not approve new devices or uses, Edwards may be unable to sell those products or expand their use.
- 2Manufacturing, quality, safety, or delivery problems at Edwards or its suppliers could interrupt access to implanted heart valves and other devices.
- 3If insurers or government health programs restrict coverage or reduce payments, hospitals may buy fewer devices or seek lower prices.
À propos de Edwards Lifesciences Corporation
Edwards makes devices that replace or repair damaged heart valves. Some are delivered through a catheter, a thin tube passed through a blood vessel, while others are implanted during open-heart surgery. Hospitals and heart specialists use these devices to treat diseases affecting the aortic, mitral, and tricuspid valves.
- Siège
- Irvine, California, United States
- Fondée en
- 1958
- Effectif
- Approximately 16,000 (December 31, 2025, medium)
- Cotée sur
- New York Stock Exchange
- Clôture de l'exercice
- December 31
Construit à partir des documents déposés par Edwards Lifesciences Corporation auprès de la Securities and Exchange Commission (SEC), le gendarme boursier américain. Les chiffres sont tels que publiés, l’historique par action étant retraité sur la base d’actions d’aujourd’hui. Ceci décrit une entreprise — ce n’est pas un conseil en investissement ni une recommandation d’acheter ou de vendre.
